UNSPSC 51312308: Diphenhydramine citrate

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4OD433S209. European Medicines Agency schedules Diphenhydramine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01768MIG. Diphenhydramine citrate generally arises in the molecular formula C17H21NO.C6H8O7. The term 'diphenhydramine citrate' is a U.S. Pharmacopeial Convention designation.

Most nations, for tariff and trade purposes, schedule diphenhydramine citrate under HS 29221980 and SITC 51461. As of Q4 2014, DIPHENHYDRAMINE CITRATE remains US FDA's Preferred Term for this commodity. Diphenhydramine citrate bears US NLM identifiers UMLS ID C0282144 and NCI Concept Code C82274. SMILES: CN(C)CCOC(C1CCCCC1)C2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51312308 Diphenhydramine citrate is a Commodity code that captures state and local procurement of specific pharmaceutical products, though recent opportunities show the code tags broader pharmaceutical and medical supply acquisitions including naloxone, over-the-counter products, and direct-to-manufacturer prescription programs. State and local governments soliciting under this code span county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Seminole County, Florida sought naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission issued an exploratory RFI on direct-to-manufacturer prescription fulfillment; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, including Oregon. The work involves sourcing FDA-compliant finished pharmaceutical goods, managing NDC coding and product specifications, coordinating with authorized drug wholesalers, and ensuring compliance with supply-chain security and manufacturing-practice standards.

Recent activity concentrates in the Upper Midwest and Southeast. The Minnesota MMCAP cooperative represents the largest-scope recent opportunity, with an RFP for generic pharmaceuticals and OTC products due March 26, 2026, requiring vendor compliance with cGMP, DSCSA, and relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with a two-year initial contract term and optional extensions through June 30, 2028. Seminole County's IFB 60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, a two-year term with optional one-year renewal, and a three-month probationary termination clause. The Texas HHS RFI (HHS0017013), issued April 3, 2026, does not represent a formal award-stage procurement but serves as preliminary market intelligence gathering on direct-to-manufacturer pharmacy initiatives. No dollar values or set-aside designations appear in the available solicitation materials.